ClinicalTrials.gg
TerminatedNCT03259516Updated Apr 5, 2019

Nivolumab With Chemotherapy in Refractory MDS

A Phase 1/2 interventional study of Nivolumab and Azacitidine in Myelodysplastic Syndromes, sponsored by St. Petersburg State Pavlov Medical University. Terminated at 1 site in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-05.

Sponsored by St. Petersburg State Pavlov Medical University · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Slow recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing nivolumab in Myelodysplastic Syndromes — none open to participants now, 1 under way, none of them phase 3. Nivolumab · Myelodysplastic Syndromes.

Enrollment
8th of 11
2 · median 29
Started
2017
the only one that year
Phase 1/2
2 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
St. Petersburg State Pavlov Medical University

Among the 11 studies testing nivolumab in Myelodysplastic Syndromes, this one is the 8th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1/2, and was the 7th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 11 studies testing nivolumab in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

Where they have run

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing nivolumab in Myelodysplastic Syndromes as a file.
02

Study summary

There is evidence of involvement of checkpoint pathways, including PD-1, in the pathogenesis and resistance of myelodysplastic syndrome (MDS). However monotherapy with checkpoint inhibitors was ineffective in a number of studies, indicating the presence of several mechanisms of resistance. This pilot study evaluates the safety and preliminary efficacy of nivolumab combination with currently existing treatments in MDS patients who failed at least one line of therapy. The study evaluates if there is a combination which induces objective responses.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • myelodysplastic syndrome
  • nivolumab
  • 5-azacitidine
  • cytarabine
  • melphalan
  • all-trans retinoic acid
  • lymphodepletion
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with myelodysplastic syndrome (MDS) (up to 20% blasts) of any risk. Patients with lower risk MDS (low and int-1 by IPSS) should have failed prior non-hypomethylating agent therapy (ie growth factors or lenalidomide). Patients with higher risk MDS (int-2 or high by IPSS) should have failed prior at least one therapy with a hypomethylating agent or Ara-C.
  • Age 18 years or older.
  • No severe organ dysfunction: creatinine \<=2.5 x ; serum \<=2.5 x ULN; and ALT \<=5 x ULN.
  • index >=70%
  • Females of must have a negative serum or urine beta human chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use an effective to avoid pregnancy for 24 weeks
  • Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 24 weeks after the last dose of nivolumab.

Exclusion criteria

Exclusion Criteria:

  • Another requiring treatment at the time of inclusion
  • History of interstitial lung disease or pneumonitis
  • Patients with any other known concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes; cardiovascular disease including congestive heart failure Class III or IV, myocardial infarction within 6 months, and poorly controlled hypertension; chronic renal failure; or active uncontrolled infection) which, in the opinion of the investigator could compromise participation in the study
  • Active, known or suspected disease requiring treatment at the time of inclusion
  • Pregnancy or breastfeeding
  • Patients unwilling or unable to comply with the protocol
  • Somatic or psychiatric disorder making the patient unable to sign
  • Prior treatment with , anti-PD-L1, or anti-CTLA4 therapy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Nivo + FC

    Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days

    Drug: Nivolumab · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Nivo + LDAC + ATRA

    Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd

    Drug: Nivolumab · Drug: Cytarabine · Drug: all trans retinoic acid

  • Experimental
    Nivo + LDAC + Sildenafil

    Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid

    Drug: Nivolumab · Drug: Cytarabine · Drug: Sildenafil

  • Experimental
    Nivo + Melphalan

    Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days

    Drug: Nivolumab · Drug: Melphalan

  • Experimental
    Nivo + 5-aza

    Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days

    Drug: Nivolumab · Drug: Azacitidine

Interventions

  • 1 mg/kg by vein on Days 1 and 15 of a 28 day cycle

    Also known as: Opdivo

  • 75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle

    Also known as: 5-azacitidine, Vidaza

  • 25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.

  • 300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.

  • 10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle

    Also known as: Ara-C, LDAC

  • 45 mg/m2 per os daily during the whole course of treatment

    Also known as: ATRA

  • 20 mg per os three times a day during the whole course of treatment

  • 2 mg per os daily during the whole course of treatment

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Overall response rate (ORR) defined as complete response plus partial response (CR + PR) and hematological improvement (HI). MDS International Working Group criteria will be used to assess response.

    Time frame: 6 months

Secondary outcomes

  1. Treatment-related adverse events as assessed by CTCAE v4.03

    Toxicity parameters based on NCI CTCAE 4.03 grades: hematological toxicity (CBC), hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), fatigue (attending physician assessment), rash (attending physician assessment), colitis (attending physician assessment), pneumonitis (attending physician assessment), autoimmune disorders (level of hormones, presence of autoimmune antibodies, attending physician assessment).

    Time frame: 6 months

  2. Infectious complications

    Incidence of severe bacterial, fungal and viral infections incidence based on laboratory confirmation and attending physician assessment

    Time frame: 6 months

07

Study locations

1 site
  • First Pavlov State Medical University of St. Petersburg
    Saint-Petersburg, 197089, Russian Federation
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Dec 2018, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 23, 2017
StartActual
May 25, 2017
Primary completionActual
Dec 25, 2018
CompletionActual
Dec 25, 2018
Last update
Apr 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03259516
Lead sponsor
St. Petersburg State Pavlov Medical University
Responsible party
Ivan S Moiseev (Vice-director for science, R.M. Gorbacheva memorial institute, St. Petersburg State Pavlov Medical University) — Principal investigator
First posted
Aug 23, 2017
Start date
May 25, 2017
Primary completion
Dec 25, 2018
Completion
Dec 25, 2018
Last update
Apr 5, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion